rs1555286303
- chr13-32356588-CTCTGCGTGTTCTCATAAACAGGTATGTGTTTGTCTACAATACTGATGGCTTTTATGACAGAGTGTAATTTTATTTCATTAACTAGTATCTACAAATGGCTTTGTTTAAAGAATGAACACATTAGTGCAGGAATGGATGAATGAAATCATCATATTTTCTAATTAGCCTGCAGTGGCAGCCTCTGGCCCCTTGCTAGGCCTGCCTCATCCTGCTAAAGTGATCTGTGCTTCCAAATTACTACTTCTTTTCCCCCTTCAAATCTTTCTTATTTTGTCATTGTAAA-C
 - rs1555286303
 - NM_000059.4:c.7598_7617+263del
 
Variant summary
Our verdict is Pathogenic. The variant received 10 ACMG points: 10P and 0B. PVS1PP5_Moderate
The NM_000059.4(BRCA2):c.7598_7617+263del(p.Ala2534TyrfsTer20) variant causes a frameshift, splice donor, splice region, intron change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. It is difficult to determine the true allele frequency of this variant because it is of type DEL_BIG, and the frequency of such variant types in population databases may be underestimated and unreliable. Variant has been reported in ClinVar as Pathogenic (★). Synonymous variant affecting the same amino acid position (i.e. S2533S) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000059.4 frameshift, splice_donor, splice_region, intron
Scores
Clinical Significance
Conservation
Publications
- breast-ovarian cancer, familial, susceptibility to, 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), ClinGen
 - Fanconi anemia complementation group D1Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, ClinGen, G2P
 - pancreatic cancer, susceptibility to, 2Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
 - sarcomaInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
 - hereditary breast ovarian cancer syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
 - Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
 - medulloblastomaInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
 
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 10 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt | 
|---|---|---|---|---|---|---|---|---|---|---|
| BRCA2 | ENST00000380152.8  | c.7597_7617+262del | p.Ser2533_Gln2539del | splice_donor_variant, conservative_inframe_deletion, splice_region_variant, intron_variant | Exon 15 of 27 | 5 | NM_000059.4 | ENSP00000369497.3 | ||
| BRCA2 | ENST00000530893.7  | c.7228_7248+262del | p.Ser2410_Gln2416del | splice_donor_variant, conservative_inframe_deletion, splice_region_variant, intron_variant | Exon 15 of 27 | 1 | ENSP00000499438.2 | |||
| BRCA2 | ENST00000614259.2  | n.7597_7617+262del | splice_donor_variant, splice_region_variant, intron_variant, non_coding_transcript_exon_variant | Exon 14 of 26 | 2 | ENSP00000506251.1 | 
Frequencies
GnomAD3 genomes  Cov.: 31 
GnomAD4 genome  Cov.: 31 
ClinVar
Submissions by phenotype
Hereditary breast ovarian cancer syndrome    Pathogenic:1 
This sequence change deletes 283 nucleotides from exon 15 of the BRCA2 mRNA (c.7598_7617+263del), causing a frameshift at codon 2534. This creates a premature translational stop signal 6 positions downstream and is expected to result in an absent or disrupted protein product. While this particular variant has not been reported in the literature, truncating variants in BRCA2 are known to be pathogenic (PMID: 20104584). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at